{"id":"preoperative-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"30-60%","effect":"Fatigue"},{"rate":"50-80%","effect":"Hair loss"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach aims to make the surgery less invasive and reduce the risk of cancer recurrence. Chemotherapy is typically administered over several weeks or months before the scheduled surgery.","oneSentence":"Preoperative chemotherapy involves administering chemotherapy before surgery to reduce tumor size and improve surgical outcomes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:04.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of tumor size before surgery"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT00512304","phase":"PHASE2","title":"Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2007-08","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT06123754","phase":"PHASE3","title":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","status":"RECRUITING","sponsor":"3D Medicines (Sichuan) Co., Ltd.","startDate":"2023-11-17","conditions":"Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT07492225","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-08-15","conditions":"Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma","enrollment":120},{"nctId":"NCT05447559","phase":"PHASE4","title":"Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study","status":"RECRUITING","sponsor":"Monash University","startDate":"2023-02-07","conditions":"Surgical Site Infection","enrollment":9180},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT03068663","phase":"NA","title":"Microbiota and the Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Jean Perrin","startDate":"2017-05-23","conditions":"Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT04894643","phase":"NA","title":"Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2020-09-14","conditions":"Pancreatic Cancer, Proton Therapy","enrollment":10},{"nctId":"NCT07479407","phase":"NA","title":"Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Hôpital du Valais","startDate":"2026-04","conditions":"Locally Advanced Non-small Cell Lung Cancer (NSCLC)","enrollment":74},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT06412510","phase":"PHASE1, PHASE2","title":"Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-09-05","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma","enrollment":22},{"nctId":"NCT04031677","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-01-20","conditions":"Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma","enrollment":250},{"nctId":"NCT07478185","phase":"NA","title":"Prehab for Pancreatic Cancer Surgery","status":"NOT_YET_RECRUITING","sponsor":"University of Massachusetts, Worcester","startDate":"2026-02","conditions":"Pancreatic Cancer, Adult, Prehabilitation","enrollment":20},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT07469202","phase":"PHASE4","title":"CYTALUX Dose Extension Study","status":"NOT_YET_RECRUITING","sponsor":"On Target Laboratories, LLC","startDate":"2026-05-15","conditions":"Cancer in the Lung, Ovarian Cancer","enrollment":106},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT07457346","phase":"PHASE2","title":"A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Head and Neck Cancer Squamous Cell Carcinoma","enrollment":76},{"nctId":"NCT07457359","phase":"PHASE2","title":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-04","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":18},{"nctId":"NCT02455791","phase":"NA","title":"Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-24","conditions":"Breast Cancer","enrollment":43},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT02812420","phase":"EARLY_PHASE1","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-07","conditions":"Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant","enrollment":54},{"nctId":"NCT00616967","phase":"PHASE2","title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-05","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT00797719","phase":"PHASE1, PHASE2","title":"Short Neoadjuvant Hemithoracic IMRT for MPM","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-10","conditions":"Malignant Pleural Mesothelioma","enrollment":104},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07276880","phase":"PHASE2","title":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-03","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma","enrollment":32},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT03483038","phase":"PHASE2","title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2018-12-13","conditions":"Pancreatic Adenocarcinoma","enrollment":45},{"nctId":"NCT06078709","phase":"PHASE2","title":"Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-20","conditions":"Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8","enrollment":99},{"nctId":"NCT07176182","phase":"PHASE2","title":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-03-01","conditions":"Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":236},{"nctId":"NCT06254183","phase":"PHASE4","title":"Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy(LSG)","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-12-01","conditions":"Acute Kidney Injury, Obesity (BMI > 35)","enrollment":90},{"nctId":"NCT03943173","phase":"EARLY_PHASE1","title":"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-07","conditions":"BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation","enrollment":15},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT05567835","phase":"PHASE2","title":"A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2024-03-06","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":3},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT05464082","phase":"PHASE2","title":"Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-01-06","conditions":"Breast Cancer Recurrent","enrollment":80},{"nctId":"NCT07421661","phase":"","title":"Effect of Epilepsy and Antiepileptic Drug Therapy on Gastric Motility and Emptying With Point-Of-Care Gastric Ultrasound","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2026-04-01","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02728076","phase":"NA","title":"MRI-Based Preoperative Accelerated Partial Breast Irradiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2016-07-29","conditions":"Breast Cancer","enrollment":39},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT07413146","phase":"NA","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy","enrollment":100},{"nctId":"NCT03520491","phase":"PHASE2","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-04-25","conditions":"Bladder Cancer","enrollment":52},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT06068985","phase":"PHASE2","title":"Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2024-09-05","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":63},{"nctId":"NCT07405476","phase":"PHASE2","title":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03-01","conditions":"Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma","enrollment":38},{"nctId":"NCT07142369","phase":"NA","title":"Synovial Fluid Withdrawal or PRP Injection For Acute ACL Tears and Cytokines","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-05","conditions":"Posttraumatic Osteoarthritis, Anterior Cruciate Ligament (ACL) Rupture","enrollment":99},{"nctId":"NCT06449313","phase":"PHASE2","title":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2026-04","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":21},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT05412225","phase":"PHASE1","title":"A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-06-06","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":60},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT05415709","phase":"EARLY_PHASE1","title":"Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-06-13","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":45},{"nctId":"NCT07401199","phase":"","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","status":"NOT_YET_RECRUITING","sponsor":"Qun Zhao","startDate":"2026-02-05","conditions":"Gastric Cancer (GC), Locally Advanced Gastric Cancer","enrollment":2000},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT07233928","phase":"NA","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2026-02-06","conditions":"Early Breast Cancer, Metastatic Breast Cancer","enrollment":1050},{"nctId":"NCT05415215","phase":"PHASE3","title":"A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-07-05","conditions":"Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer","enrollment":346},{"nctId":"NCT06268210","phase":"PHASE2","title":"Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-02-07","conditions":"Non-small Cell Lung Cancer","enrollment":160},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT05167487","phase":"","title":"Pathological Response After Neoadjuvant Treatment on NSCLC","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2021-12-13","conditions":"Stage IIIA Non-small Cell Lung Cancer","enrollment":150},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT04700124","phase":"PHASE3","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-21","conditions":"Bladder Cancer","enrollment":808},{"nctId":"NCT06501482","phase":"PHASE3","title":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-06-27","conditions":"Colorectal Cancer, Colorectal Liver Metastases","enrollment":254},{"nctId":"NCT07386158","phase":"PHASE2","title":"Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-10","conditions":"Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy","enrollment":21},{"nctId":"NCT02876302","phase":"PHASE2","title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-24","conditions":"Inflammatory Breast Cancer (IBC)","enrollment":23},{"nctId":"NCT07383818","phase":"PHASE2","title":"Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-02-01","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":111},{"nctId":"NCT05621564","phase":"","title":"Pre-operative Therapy in Breast Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2022-11-01","conditions":"Breast Cancer","enrollment":488},{"nctId":"NCT04799535","phase":"","title":"Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-01","conditions":"Breast Carcinoma, Breast Neoplasm","enrollment":550},{"nctId":"NCT04623554","phase":"NA","title":"Pre-operative Exercise During Neoadjuvant Chemotherapy in Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2021-06-23","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT07381400","phase":"PHASE2","title":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","status":"NOT_YET_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT07377747","phase":"","title":"Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma","status":"RECRUITING","sponsor":"Australia and New Zealand Sarcoma Association","startDate":"2024-09-05","conditions":"Retroperitoneal Liposarcoma","enrollment":100},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05806515","phase":"PHASE2","title":"Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-03-01","conditions":"Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8","enrollment":44},{"nctId":"NCT04481113","phase":"PHASE1","title":"Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-06-07","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":8},{"nctId":"NCT07335380","phase":"PHASE1","title":"Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-04","conditions":"Oral Cavity Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07372079","phase":"PHASE2","title":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-04-05","conditions":"Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":40},{"nctId":"NCT06688786","phase":"NA","title":"A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT06997094","phase":"PHASE1","title":"Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-23","conditions":"Human Papillomavirus-Negative Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT07359443","phase":"PHASE1","title":"Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2025-05-21","conditions":"Esophageal Adenocarcinoma, Esophageal Adenocarcinoma (EAC), Adenocarcinoma - Gastroesophageal Junction (GEJ)","enrollment":39},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT03257163","phase":"PHASE2","title":"Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-09-29","conditions":"Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency","enrollment":40},{"nctId":"NCT07346248","phase":"","title":"Postoperative Complications After Neoadjuvant Chemoradiotherapy or Short-course Radiotherapy and Total Neoadjuvant Treatment: a Multicentric Retrospective Cohort Study","status":"ENROLLING_BY_INVITATION","sponsor":"Istituto Clinico Humanitas","startDate":"2025-07-21","conditions":"Adult Patients With Locally Advanced Rectal Cancer Indicated to Neoadjuvant Therapy and Surgery","enrollment":266},{"nctId":"NCT07290985","phase":"PHASE2","title":"AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas","status":"NOT_YET_RECRUITING","sponsor":"American Association for Cancer Research","startDate":"2026-03-01","conditions":"Gastroesophageal Adenocarcinoma","enrollment":121},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340151","phase":"NA","title":"Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02","conditions":"Adenocarcinoma of the Pancreas","enrollment":40},{"nctId":"NCT05594290","phase":"PHASE2","title":"Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-12-07","conditions":"Merkel Cell Carcinoma","enrollment":36},{"nctId":"NCT04796818","phase":"NA","title":"An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-12","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma","enrollment":70},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT04523818","phase":"PHASE1","title":"Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-11","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8","enrollment":25},{"nctId":"NCT03258320","phase":"PHASE2, PHASE3","title":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Prostate Cancer Patients","enrollment":300},{"nctId":"NCT02213497","phase":"PHASE1","title":"Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2014-04","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT04204811","phase":"NA","title":"Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-16","conditions":"Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5116,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folinic acid, Irinotecan, fluorouracil, oxaliplatin","neoadjuvant chemotherapy","doxorubicin+cyclophosphamide and paclitaxel"],"phase":"phase_3","status":"active","brandName":"Preoperative chemotherapy","genericName":"Preoperative chemotherapy","companyName":"CNAO National Center of Oncological Hadrontherapy","companyId":"cnao-national-center-of-oncological-hadrontherapy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Preoperative chemotherapy involves administering chemotherapy before surgery to reduce tumor size and improve surgical outcomes. Used for Reduction of tumor size before surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}